- Home
- MYND vs CMMB Comparison
MYND vs CMMB Comparison
Compare MYND & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYND | CMMB |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 19.9M |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MYND | CMMB |
|---|---|---|
| Price | $0.39 | $2.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 43.7K | ★ 98.2K |
| Earning Date | 05-27-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $67.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $1.35 |
| 52 Week High | $1.15 | $3.55 |
Technical Indicators
Market Signals| Indicator | MYND | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 84.13 |
| Support Level | $0.30 | $1.47 |
| Resistance Level | $0.49 | $2.86 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 27.97 | 87.54 |
Price Performance
Historical ComparisonAbout MYND Mynd.ai Inc.
Mynd.ai Inc provides world'wide, end-to-end, learning solutions and collaboration tools to help teachers, schools, students, and professionals realize their greatest potential. The company has single reporting segment. The company has presence in United States and Rest of world. The company generates majority of revenue from United States.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.